Concomitant ruxolitinib induction and maintenance with cytara-bine based chemotherapy in secondary acute myelogenous leu-kemia evolving from myeloproliferative neoplasm

Seoul National University Hospital0 个研究点目标入组 17 人开始时间: 待定最近更新: 2019年3月11日

适应症

试验速览

暂无简介。

•A. Cytologically confirmed AML following MPN
•B. Age 18 years or older
•C. ECOG performance status 2 or better
•D. Adequate physical condition that could tolerate cytotoxic induction chemotherapy judged by investigator:
•Serum creatinine = 2.5 mg/dl
•·ALT (SGOT) and/or AST (SGPT) equal to or than 1.5 x upper limit of normal
•E. No other chemotherapy within 2 weeks except hydroxyurea
•F. Life expectancy of = 3 months
•G. For women of childbearing age, it should be confirmed that they are not pregnant and that they should be contraception during the study period and for up to 4 weeks after the end of the study
•H. Male should agree to the barrier method during the study period and up to four weeks af-ter the end of the study
•I. Signed and dated informed consent of document

•A. uncontrolled infection
•B. Pregnancy or breast feeding
•C. Pregnant or child-bearing women without will of contraception
•D. Patients who received other chemotherapy within 2 weeks of the study enrollment
•E. No informed consent
•F. patient with acute promyelocytic leukemia
•G. Patients participating in other clinical studies at the time of registration
•H. prior hypersensitiivty to ruxolitinib
•I. Other severe acute or chronic medical or psychiatric condition
•J. Prior treatment with ruxolitinib

发起方